ClinicalTrials.gg
Not yet recruitingNCT05798936Updated Apr 5, 2023

Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst

A Phase 4 interventional study of Polidocanol and Alcohol in Benign Thyroid Nodule, Thyroid Lump and Thyroid Cyst, sponsored by Assiut University. Not yet recruiting. Open to participants aged 10 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Assiut University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
10 Years to 75 Years
Sex
All
01

Study summary

This study aims to compare the efficacy and safety of ultrasound-guided percutaneous ethanol injection and percutaneous polidocanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.

Read the detailed description

Thyroid nodules are characterized by excessive structural growth, functional transformation, and/or cystic degeneration of one or several areas within the gland. According to various studies, 15-30% of thyroid nodules are cystic or predominantly cystic. Around 5% of patients with thyroid nodules may experience compressive symptoms or cosmetic concerns, and treatment may be required in these cases.

Simple aspiration is generally the initial management for the purpose of diagnosis and cyst volume reduction. However, the recurrence rate has been reported to be high (40% to 59%), depending on the number of aspirations and extent of fluid evacuation. After simple fine-needle aspiration, most cystic lesions (around 80%) refill and enlarge over time.

Surgery is a long-established therapeutic option for benign thyroid nodules. However, the cost of thyroid surgery, risk of temporary or permanent complications, and impact on quality of life remain relevant concerns.

Ultrasound-guided percutaneous ethanol injection (PEI) The mechanism of ethanol sclerotherapy is that ethanol induces cellular dehydration and protein denaturation, which are followed by coagulation necrosis, reactive fibrosis, and small-vessel thrombosis.

As regard (PEI)Pain is the most common side effect, other mild side effects or complications occurred in small numbers of patients like: Facial flushing, Mild dizziness, Intracystic haemorrhage, drunken sense, Perithyroidal leakage. There are other side effects, including transient vocal cord palsy, respiratory distress requiring emergency surgical treatment, and venous thrombosis, in sporadic cases.

Percutaneous Polidocanol sclerotherapy (PPI) may be a potential alternative to ethanol for the treatment of benign cystic and predominantly cystic thyroid nodules.Polidocanol is a liquid detergent sclerosant developed in 1936 as a topical and local anaesthetic consisting of 95% hydroxy poly ethoxydodecane and 5% ethyl alcohol. It has been used as a treatment for hemorrhoidal disease, venous malformations, symptomatic hepatic cysts, renal cysts, gastric varices, and digital mucous cysts.

The mechanism of treating cyst is probably destroying endothelial cells of capsular wall which causes aseptic inflammation; thus endothelial tissue atrophies and cyst cavity adhere and occlude.

The side effects are mild including mild localized pain and mild or moderate fever after PPI. So, PPI could be a safe and effective alternative to treat benign cystic or predominant cystic thyroid nodules.

02

Conditions studied

  • Benign Thyroid Nodule
  • Thyroid Lump
  • Thyroid Cyst
03

In context

Cysts

67 studies on the registry are indexed under Cysts; 16 are open to participants now.

This study's planned enrollment of 30 is below the median of 48 across 40 interventional studies indexed under Cysts.

Browse Cysts studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Single cystic or predominantly cystic nodules.
  • Pressure symptoms or cosmetic problems.
  • No malignant or indeterminate cytologic results after ultrasound-guided fine-needle aspiration.
  • Normal serum thyroid hormone levels

Exclusion criteria

Exclusion Criteria:

  • Association of a nodules showing malignant features on us examinations.
  • Malignant or indeterminate cytologic results after ultrasound-guided fine-needle aspiration.
  • Abnormal serum thyroid hormone levels
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Polidocanol group

    Polidocanol is injected in the thyroid cyst under ultrasound guidance.

    Drug: Polidocanol

  • Experimental
    Alcohol group

    Alcohol is injected in the thyroid cyst under ultrasound guidance.

    Drug: Alcohol

Interventions

  • Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.

    Also known as: Polidocanol solution

  • Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.

    Also known as: Alcohol Ethyl

06

What researchers measure

Primary outcomes

  1. Size of the thyroid cystic nodule after sclerosing agent injection (polidocanol versus alcohol)

    Size of the thyroid cyst is measured by ultrasound after 3 months of sclerosing agent injection

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05798936
Lead sponsor
Assiut University
Responsible party
Amna Ahmed Ali Ahmed (Doctor, Assiut University) — Principal investigator
First posted
Apr 5, 2023
Start date
Apr 1, 2023 (estimated)
Primary completion
May 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Apr 5, 2023

Study contacts

Amna Ahmed
Contact
amnabkar76@gmail.com
01095339383
Hany Seif
Contact
hanyseifrad@yahoo.com
01005618665

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polidocanol · Ethanol

Start the discussion